A 28-year-old man presents with a 5-day history of fever, productive cough with blood-tinged sputum, and pleuritic chest pain. He has no significant past medical history. Chest X-ray shows multiple cavitary lesions in the right upper lobe. Sputum culture grows Gram-positive cocci in clusters that are catalase-positive, coagulase-positive, and resistant to oxacillin. The patient is started on vancomycin. Which of the following best explains the oxacillin resistance in this isolate?

Explanation

## Oxacillin Resistance in Methicillin-Resistant S. aureus (MRSA) ### Mechanism of Resistance: mecA Gene and Altered PBPs **Key Point:** MRSA resistance to oxacillin (and all beta-lactams) is caused by the **mecA gene**, which encodes an altered penicillin-binding protein (PBP2a) with very low affinity for beta-lactam antibiotics. ### Molecular Basis of MRSA 1. **mecA gene origin** → Acquired from *Staphylococcus sciuri* via horizontal gene transfer 2. **Location** → Carried on the **Staphylococcal Chromosome Cassette mec (SCCmec)** 3. **Gene product** → PBP2a (also called FtsI), a transpeptidase with altered active site 4. **Mechanism** → PBP2a has ~1000-fold lower affinity for beta-lactams compared to native PBPs 5. **Consequence** → Even at high beta-lactam concentrations, PBP2a continues cell wall synthesis, conferring resistance ### Why This Is Not Beta-Lactamase Production **High-Yield:** MRSA is **NOT** primarily resistant via beta-lactamase. While some MRSA strains produce beta-lactamase, this is a secondary mechanism and is NOT the defining feature of MRSA. - Beta-lactamase-producing S. aureus (BLPSA) is susceptible to **beta-lactamase-stable agents** like oxacillin - MRSA is resistant to **all beta-lactams**, including oxacillin and nafcillin - This pan-beta-lactam resistance is pathognomonic for mecA-mediated resistance ### Comparison of S. aureus Resistance Mechanisms | Resistance Type | Mechanism | Oxacillin Susceptibility | Clinical Significance | |---|---|---|---| | **MSSA** (Methicillin-Susceptible) | Native PBPs with normal beta-lactam affinity | **Susceptible** | Treat with oxacillin/nafcillin | | **MRSA** (Methicillin-Resistant) | **PBP2a (mecA gene)** — altered active site | **RESISTANT** | Treat with vancomycin, linezolid, dalbavancin | | **BLPSA** (Beta-Lactamase-Producing) | Beta-lactamase enzyme | **Susceptible** to oxacillin | Treat with oxacillin (enzyme-stable) | **Clinical Pearl:** The oxacillin **E-test** or **broth microdilution** is the gold standard for detecting MRSA. An oxacillin MIC ≥2 μg/mL confirms MRSA. PCR detection of *mecA* is also used in reference labs. ### SCCmec Types and Epidemiology **Mnemonic:** **SCCmec Types I–V** (and newer VI–XIII) - **Type I, II, III** → Hospital-acquired MRSA (HA-MRSA), larger cassettes, multiple resistance genes - **Type IV, V** → Community-acquired MRSA (CA-MRSA), smaller cassettes, often PVL-positive - This patient's cavitary lung disease suggests possible CA-MRSA with PVL toxin ### Clinical Context: Cavitary Pneumonia The presence of **cavitary lesions** in a young, previously healthy patient is suggestive of: - **Community-acquired MRSA (CA-MRSA)** with Panton-Valentine leukocidin (PVL) - PVL causes tissue necrosis and cavitation - Vancomycin is appropriate empiric therapy pending susceptibilities **Warning:** Do NOT confuse MRSA resistance mechanisms: - ~~Beta-lactamase~~ → This would leave oxacillin susceptibility intact - ~~Efflux pumps~~ → Not the primary mechanism in MRSA; more relevant to fluoroquinolone resistance - ~~Lipopolysaccharide~~ → S. aureus is Gram-positive; LPS is a Gram-negative feature